Northern Gritstone expands to Bay Area in first international move after five years

Northern Gritstone, the spinout investor backed by universities across the North of England, has announced an international expansion into the Bay Area — its first move beyond the UK in approximately five years of operations.

The firm, which backs early-stage companies emerging from Northern university research programmes, said the expansion is designed to connect its portfolio with deeper pools of US capital, talent and networks. Central to the plan is the hiring of a venture partner based in the United States, which CEO Duncan Johnson has described as a key differentiator for portfolio companies.

Northern Gritstone's stated rationale for the Bay Area move centres on giving portfolio companies access to deeper pools of US capital, talent and networks — a goal the firm says will be supported by a dedicated US-based venture partner hire.

Why the Bay Area

The choice of the Bay Area as Northern Gritstone's US base aligns with the firm's stated ambition to embed its portfolio companies within one of the most capital-dense technology and life sciences ecosystems globally. According to the firm's official announcement, Johnson also spoke to Jess Jones at The Times about the expansion — Jones is described in that announcement as a Senior Reporter at the publication, though The Fin Desk has not independently verified that title.

The venture partner hire is presented by the firm as a structural commitment rather than an advisory arrangement, intended to give Northern Gritstone a permanent operational presence in the US market rather than a visiting relationship.

Portfolio Context

Northern Gritstone's existing portfolio spans two broad sectors: life sciences and technology. Verified portfolio companies in the life sciences space include Apini Therapeutics, Crucible Therapeutics, Cytotrait and Pencil Biosciences, among others, according to the firm's portfolio page. The technology side of the portfolio similarly draws from spinout activity across Northern universities.

The firm has operated for approximately five years at the point of making the Bay Area announcement, placing the expansion at what management appears to regard as a natural inflection point for internationalisation.

The Exit Debate

The expansion sits alongside a debate that Johnson has engaged with publicly. In an interview with Sifted, the CEO addressed the question of whether selling portfolio companies to US acquirers should be regarded as a failure — a topic that carries particular resonance in UK deeptech circles, where the absence of a liquid domestic public market for early-stage science companies remains a structural constraint.

Johnson's position, as characterised in secondary reporting of that interview, is that such exits should not be treated as failures. The Fin Desk notes that the full content of the Sifted interview was not independently retrieved for this article; the paraphrase above is drawn from secondary reporting of that conversation and should be treated accordingly.

What Remains Unconfirmed

Several elements reported elsewhere in connection with this announcement have not been independently verified from retrieved primary sources and are therefore excluded from this article:

• A specific fundraising figure linked to a British Business Bank anchor commitment has appeared in coverage but the underlying source was not successfully retrieved; this figure cannot be confirmed.
• The identity of the incoming US venture partner has been referenced in coverage but the primary source for that claim was not successfully retrieved.
• A specific date for the opening of a San Francisco office has appeared in some secondary reporting but rests on sources not retrieved in full; timing should be treated as unconfirmed.

Editorial Note

The Bay Area move is editorially notable for what it signals about the internationalisation strategies available to regional deep-science investors operating outside major financial centres. For firms whose portfolio companies face a constrained domestic exit landscape, building structured US relationships earlier in the company lifecycle — rather than pursuing them reactively at exit — represents a distinct strategic posture. Whether the venture partner model delivers on that ambition will depend on execution detail not yet in the public domain.